Physician profile
Robyn D Jacoby
NPI 1487623575
$3,936.51
in general payments reported to CMS, 2019-2025
33 companies · $79.21 in 2025
The $79.21 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $1,287 · 2021: $431 · 2022: $1,142 · 2023: $276 · 2024: $96.09 · 2025: $79.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $620.00 | 2020 | |
| Shockwave Medical, INC | $617.05 | 2022 | |
| Abbvie INC. | $427.53 | 2019-2023 | |
| Allergan, INC. | $336.87 | 2019-2020 | |
| Pfizer INC. | $304.94 | 2019-2025 | |
| Bausch Health US, LLC | $283.14 | 2019-2025 | Aplenzin |
| Genzyme Corporation | $185.00 | 2019 | |
| Lilly USA, LLC | $133.77 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $121.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $100.29 | 2022-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.39 | 2019-2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $81.98 | 2020-2021 | |
| Amgen INC. | $74.28 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $65.41 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $62.92 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $60.48 | 2020 | |
| Almatica Pharma LLC | $37.87 | 2021 | |
| Astellas Pharma US INC | $36.77 | 2019-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.53 | 2021 | |
| Sanofi Pasteur INC. | $27.51 | 2019-2023 | |
| Antares Pharma, INC. | $24.91 | 2019 | |
| Medtronic, INC. | $23.10 | 2023 | Intellis Adaptivestim |
| Tms Neurohealth Centers INC. | $22.06 | 2025 | Tms Neurohealth Centers INC. |
| Alnylam Pharmaceuticals INC. | $21.19 | 2022 | |
| Exact Sciences Corporation | $18.24 | 2023 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $17.88 | 2023 | |
| Promius Pharma LLC | $17.01 | 2019 | |
| Avion Pharmaceuticals | $15.53 | 2021 | |
| Horizon Therapeutics Plc | $14.65 | 2020 | |
| Phadia US INC. | $14.31 | 2022 | |
| Therapeuticsmd, INC. | $14.10 | 2021 | |
| Merck Sharp & Dohme LLC | $13.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.